On Wednesday, Lonza announced a deal with an undefined customer for two new facilities to commercialize antibody-drug conjugates at its Visp, Switzerland, site as the contract drugmaker extends its work with the technology.
“Long-term collaboration with a global biopharma company will generate around 200 new jobs in the Visp bio park with operations required to begin from end-2022,” Lonza said in a report.
